Nutriband Inc.'s AVERSA(TM) Technology: Combating Drug Abuse Through Innovation

What is AVERSA(TM) technology?

AVERSA(TM) is Nutriband Inc.’s transdermal abuse-deterrent technology, designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, such as fentanyl.

Why is Nutriband’s new patent significant?

The new U.S. patent expands Nutriband’s domestic IP coverage for AVERSA(TM), enhancing the company’s ability to combat drug abuse and contribute to solving the opioid crisis through innovative drug safety technologies.

How does AVERSA(TM) contribute to drug safety?

AVERSA(TM) aims to prevent abuse at the product level by deterring misuse and accidental exposure of transdermal drugs, thereby enhancing safety across multiple therapeutic categories.

What is the current state of the opioid crisis in the U.S.?

The opioid crisis remains a persistent public health emergency, with over 100,000 Americans dying each year from drug overdoses, a significant proportion linked to synthetic opioids like fentanyl. More information can be found here.

Where can I find more updates about Nutriband Inc.?

The latest news and updates relating to Nutriband Inc. (NASDAQ: NTRB) are available in the company’s newsroom at https://ibn.fm/NTRB.

What makes Nutriband’s approach to drug safety unique?

Nutriband focuses on preventing abuse at the product level through innovative technologies like AVERSA(TM), offering a novel solution to the challenge of balancing patient access with safety and deterrence.

How can I learn more about BioMedWire and its services?

BioMedWire is a specialized communications platform focusing on Biotechnology, Biomedical Sciences, and Life Sciences. More about their services can be found at https://www.biomedwire.com/.